Disc Medicine, Inc. (IRON)

NASDAQ: IRON · IEX Real-Time Price · USD
46.27
+7.11 (18.16%)
At close: Jun 14, 2024, 4:00 PM
46.99
+0.72 (1.56%)
After-hours: Jun 14, 2024, 7:57 PM EDT
18.16%
Market Cap 1.14B
Revenue (ttm) n/a
Net Income (ttm) -80.60M
Shares Out 24.72M
EPS (ttm) -3.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,195,192
Open 39.16
Previous Close 39.16
Day's Range 39.11 - 48.45
52-Week Range 25.60 - 77.60
Beta n/a
Analysts Buy
Price Target 62.20 (+34.43%)
Earnings Date Aug 9, 2024

About IRON

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the tre... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 74
Stock Exchange NASDAQ
Ticker Symbol IRON
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for IRON stock is "Buy." The 12-month stock price forecast is $62.2, which is an increase of 34.43% from the latest price.

Price Target
$62.2
(34.43% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Disc Medicine Announces Underwritten Offering of Common Stock

WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...

15 hours ago - GlobeNewsWire

Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress

WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

16 hours ago - GlobeNewsWire

Disc Medicine to Participate in the Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t...

15 days ago - GlobeNewsWire

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t...

4 weeks ago - GlobeNewsWire

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t...

4 weeks ago - GlobeNewsWire

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

WATERTOWN, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t...

5 weeks ago - GlobeNewsWire

Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: HUMSYRS
2 months ago - Benzinga

Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

WATERTOWN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

2 months ago - GlobeNewsWire

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

3 months ago - GlobeNewsWire

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

3 months ago - GlobeNewsWire

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

Pamela Stephenson is an accomplished industry executive with over 25 years of global commercial leadership experience and a track record of numerous successful launches Pamela Stephenson is an accompl...

3 months ago - GlobeNewsWire

FDA Grants Orphan Drug Designation to 9MW3011

SHANGHAI , Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Orphan Drug Designation (ODD) to 9MW301...

4 months ago - PRNewsWire

Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

WATERTOWN, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

4 months ago - GlobeNewsWire

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

WATERTOWN, Mass., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

4 months ago - GlobeNewsWire

Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer

WATERTOWN, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

4 months ago - GlobeNewsWire

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

5 months ago - GlobeNewsWire

Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) (“Disc”), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization ...

6 months ago - GlobeNewsWire

Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting

WATERTOWN, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

6 months ago - GlobeNewsWire

Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting

WATERTOWN, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

6 months ago - GlobeNewsWire

Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin

WATERTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

7 months ago - GlobeNewsWire

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

WATERTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

7 months ago - GlobeNewsWire

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

7 months ago - GlobeNewsWire

Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates

WATERTOWN, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

8 months ago - GlobeNewsWire

Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce

WATERTOWN, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

8 months ago - GlobeNewsWire

Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

WATERTOWN, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

9 months ago - GlobeNewsWire